CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
影响 CAR-T 细胞疗效因素的研究进展
英文原题：Advances in research on factors affecting chimeric antigen receptor T-cell efficacy.
查看英文原题
Advances in research on factors affecting chimeric antigen receptor T-cell efficacy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法正成为治疗复发/难治性血液系统恶性肿瘤患者的有效技术。通过分析 CAR-T 治疗后肿瘤进展患者和持续缓解患者，研究发现多种因素与 CAR-T 疗效有关。本文回顾影响 CAR-T 效果的因素，包括肿瘤特征、肿瘤微环境和患者免疫功能、CAR-T 细胞结构、构建方法及体内扩增情况、淋巴清除化疗，以及既往治疗，并对相应治疗策略作初步展望。
展开英文摘要原文
Chimeric antigen receptor T-cell (CAR-T) therapy is becoming an effective technique for the treatment of patients with relapsed/refractory hematologic malignancies. After analyzing patients with tumor progression and sustained remission after CAR-T cell therapy, many factors were found to be associated with the efficacy of CAR-T therapy.
This paper reviews the factors affecting the effect of CAR-T such as tumor characteristics, tumor microenvironment and immune function of patients, CAR-T cell structure, construction method and in vivo expansion values, lymphodepletion chemotherapy, and previous treatment, and provides a preliminary outlook on the corresponding therapeutic strategies.
论文信息
- 作者
- Zhou D、Zhu X、Xiao Y
- 单位
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Cancer medicine2024 Jun
- 原文标识
- PubMed 38864474 · DOI 10.1002/cam4.7375
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →